What is United Therapeutics's accrued expenses?

United Therapeutics (UTHR) reported accrued expenses of $100.8M in Q1 2026.

How has United Therapeutics's accrued expenses changed year-over-year?

United Therapeutics's accrued expenses decreased by 34.8% year-over-year, from $154.5M to $100.8M.

What is the long-term trend for United Therapeutics's accrued expenses?

Over 5 years (2020 to 2025), United Therapeutics's accrued expenses has grown at a 12.9% compound annual growth rate (CAGR), from $39.5M to $72.6M.

United Therapeutics UTHR Accrued Expenses

Accrued Expenses at other companies

Tenet HealthcareTHC

$854M+20.3%

BridgeBio PharmaBBIO

$39.34M+17.6%

AmgenAMGN

$16.58B-3.8%

Arrowhead ResearchARWR

$20.37M+22.6%

Jazz PharmaceuticalsJAZZ

$1.02B-3.9%

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$781.5M-1.6%

Gross profit$648.1M-7.7%

Operating income$325.8M-14.9%

Net income$274.9M-14.7%

EPS (diluted)$5.82-12.2%

Balance sheet

See full

Cash & equivalents$1.3B-32.6%

Total debt$12.2M—

Total equity$5.9B-13.3%

Total assets$6.7B-13.3%

Cash flow

See full

Operating cash flow$463.3M+0.5%

CapEx$100.8M+34.6%

Free cash flow$362.5M-6.2%

Valuation

See full

Market cap$22.78B+87.7%

P/E17.7×+7.7×

P/S7.2×+3.1×

Profitability

See full

Gross margin86.6%-2.4pp

Operating margin45.3%-1.6pp

Net margin40.6%+0.2pp

FCF margin32.1%-5.6pp

Returns & leverage

See full

Return on equity20.3%+0.3pp

Debt / equity0×—

Current ratio4.8×-0.7×

Where this comes from

Reported directly by United Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about United Therapeutics's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is United Therapeutics's accrued expenses?: United Therapeutics (UTHR) reported accrued expenses of $100.8M in Q1 2026.
How has United Therapeutics's accrued expenses changed year-over-year?: United Therapeutics's accrued expenses decreased by 34.8% year-over-year, from $154.5M to $100.8M.
What is the long-term trend for United Therapeutics's accrued expenses?: Over 5 years (2020 to 2025), United Therapeutics's accrued expenses has grown at a 12.9% compound annual growth rate (CAGR), from $39.5M to $72.6M.